Table 2.

This table depicts the values that were found to be significantly related to overall survival in each study that reported these variables as well as their corresponding hazard ratios and 95% confidence intervals.

	Factors associated with OS on multivariate analysis	Hazard ratio (95% CI)	P-value
Adeberg et al. (26)	MGMT promoter methylation	0.43 (0.18,0.99)	0.048
Blumenthal et al. (25)	RPA IV (vs. III)	1.65 (1.37, 1.99)	<0.001
	RPA V (vs. III)	2.91 (2.34, 3.61)	<0.001
	MGMT unmethylated	1.72 (1.48, 2.00)	<0.001
	Male sex	1.31 (1.14, 1.50)	<0.001
Han et al. (27)	Age	1.03 (1.02,1.05)	<0.001
	KPS	3.64 (1.55,8.55)	0.003
	Biopsy (vs. STR/GTR)	2.93 (1.93, 4.45)	<0.001
Louvel et al. (28)	Male sex	1.28 (1.06,1.55)	0.012
	RTOG-RPA class 5–6	1.31 (1.08,1.58)	0.005
	Total resection (vs. partial)	0.75 (0.62,0.91)	0.004
Nathan et al. (29)	Age at craniotomy	1.031 (1.026,1.036)	<0.0001
	Female sex	0.837 (0.742,0.944)	0.0038
Osborn et al. (30)	Age > 60	1.68 (1.61,1.75)	<0.001
	Charlson/Deyo 1 (vs. 0)	1.17 (1.10,1.24)	<0.001
	Charlson/Deyo ≥ 2 (vs. 0)	1.37 (1.27,1.47)	<0.001
	Female gender	0.90 (0.87,0.94)	<0.001
	Other race (vs. white)	0.68 (0.60,0.78)	<0.001
	Tumor size 3–5cm (vs. < 3)	1.09 (1.03,1.16)	<0.001
	Tumor size >5cm (vs. < 3)	1.13 (1.06,1.20)	<0.001
	MGMT methylation	0.72 (0.65,0.81)	<0.001
	GTR (vs. STR)	0.82 (0.79,0.86)	<0.001
	Academic facility	0.91 (0.87,0.95)	<0.001
Sun et al. (32)	Age	1.018 (1.001,1.036)	0.049
Wang et al. (33)	KPS < 70	3.586 (1.644,7.822)	0.001
	Biopsy only (vs. GTR)	2.510 (1.327,4.747)	0.005
	RPA class IV (vs. III)	3.467 (1.351,8.898)	0.01
	RPA class V/VI (vs. III)	3.650 (1.077,12.369)	0.001
	Total RT dose < 36 Gy (vs. >54)	4.671 (2.241,9.737)	0.001
	No temozolomide	3.823 (1.694,8.627)	0.001

MGMT, O6-methylguanine-DNA methyltransferase; RPA, recursive partitioning analysis; KPS, Karnofsky performance status; STR, subtotal resection; GTR, gross total resection; RT, radiation therapy.